Is Rigel Pharmaceuticals Stock a Good Investment?
Rigel Pharmaceuticals Investment Advice | RIGL |
- Examine Rigel Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Rigel Pharmaceuticals' leadership team and their track record. Good management can help Rigel Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Rigel Pharmaceuticals' business and its evolving consumer preferences.
- Compare Rigel Pharmaceuticals' performance and market position to its competitors. Analyze how Rigel Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Rigel Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Rigel Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Rigel Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Rigel Pharmaceuticals is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Rigel Pharmaceuticals Stock
Researching Rigel Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 68.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Rigel Pharmaceuticals had 1:10 split on the 27th of June 2024.
To determine if Rigel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rigel Pharmaceuticals' research are outlined below:
| Rigel Pharmaceuticals is way too risky over 90 days horizon | |
| Rigel Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Rigel Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 116.88 M. Net Loss for the year was (25.09 M) with profit before overhead, payroll, taxes, and interest of 53.72 M. | |
| Rigel Pharmaceuticals currently holds about 81.64 M in cash with (5.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Rigel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3 |
Rigel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rigel Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rigel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Rigel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Rigel Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.03 | -0.05 | -0.02 | 66 | ||
2023-05-02 | 2023-03-31 | -0.1 | -0.08 | 0.02 | 20 | ||
2022-11-03 | 2022-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2022-05-03 | 2022-03-31 | -0.14 | -0.16 | -0.02 | 14 | ||
2021-11-02 | 2021-09-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2020-02-27 | 2019-12-31 | -0.08 | -0.1 | -0.02 | 25 | ||
2019-08-06 | 2019-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2019-05-07 | 2019-03-31 | -0.13 | -0.11 | 0.02 | 15 |
Know Rigel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rigel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rigel Pharmaceuticals backward and forwards among themselves. Rigel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rigel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 144.3 K | Renaissance Technologies Corp | 2024-09-30 | 141.9 K | Ing Investment Management Llc | 2024-06-30 | 118.9 K | Jane Street Group Llc | 2024-06-30 | 105.9 K | Ubs O'connor Llc | 2024-06-30 | 92.4 K | Kennedy Capital Management Inc | 2024-06-30 | 89.9 K | Squarepoint Ops Llc | 2024-06-30 | 80.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 77.4 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 75.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.8 M | Armistice Capital, Llc | 2024-06-30 | 1.6 M |
Rigel Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 458.69 M.Market Cap |
|
Rigel Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | 0.88 | 0.92 |
Determining Rigel Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Rigel Pharmaceuticals is a good buy. For example, gross profit margin measures Rigel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rigel Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Rigel Pharmaceuticals' management efficiency
Rigel Pharmaceuticals has return on total asset (ROA) of 0.0461 % which means that it generated a profit of $0.0461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.92 this year, although the value of Return On Tangible Assets will most likely fall to (0.25). At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Asset Turnover is expected to rise to 1.05 this year, although the value of Other Current Assets will most likely fall to about 4.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.65) | (1.56) | |
| Tangible Book Value Per Share | (2.44) | (2.32) | |
| Enterprise Value Over EBITDA | (16.50) | (17.32) | |
| Price Book Value Ratio | (8.81) | (8.37) | |
| Enterprise Value Multiple | (16.50) | (17.32) | |
| Price Fair Value | (8.81) | (8.37) | |
| Enterprise Value | 322.1 M | 306 M |
At Rigel Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.953 |
Basic technical analysis of Rigel Stock
As of the 23rd of November, Rigel Pharmaceuticals holds the Coefficient Of Variation of 494.65, semi deviation of 2.44, and Risk Adjusted Performance of 0.1639. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rigel Pharmaceuticals, as well as the relationship between them. Please check Rigel Pharmaceuticals downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Rigel Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 26.04 per share. Given that Rigel Pharmaceuticals has jensen alpha of 1.07, we recommend you to check out Rigel Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.Rigel Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rigel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rigel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rigel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rigel Pharmaceuticals' Outstanding Corporate Bonds
Rigel Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rigel Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rigel bonds can be classified according to their maturity, which is the date when Rigel Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Rigel Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Rigel Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1639 | |||
| Market Risk Adjusted Performance | 0.5938 | |||
| Mean Deviation | 3.53 | |||
| Semi Deviation | 2.44 | |||
| Downside Deviation | 3.28 | |||
| Coefficient Of Variation | 494.65 | |||
| Standard Deviation | 6.73 | |||
| Variance | 45.28 | |||
| Information Ratio | 0.1827 | |||
| Jensen Alpha | 1.07 | |||
| Total Risk Alpha | 0.2906 | |||
| Sortino Ratio | 0.3745 | |||
| Treynor Ratio | 0.5838 | |||
| Maximum Drawdown | 55.18 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 9.1 | |||
| Downside Variance | 10.78 | |||
| Semi Variance | 5.94 | |||
| Expected Short fall | (4.45) | |||
| Skewness | 3.98 | |||
| Kurtosis | 22.95 |
| Risk Adjusted Performance | 0.1639 | |||
| Market Risk Adjusted Performance | 0.5938 | |||
| Mean Deviation | 3.53 | |||
| Semi Deviation | 2.44 | |||
| Downside Deviation | 3.28 | |||
| Coefficient Of Variation | 494.65 | |||
| Standard Deviation | 6.73 | |||
| Variance | 45.28 | |||
| Information Ratio | 0.1827 | |||
| Jensen Alpha | 1.07 | |||
| Total Risk Alpha | 0.2906 | |||
| Sortino Ratio | 0.3745 | |||
| Treynor Ratio | 0.5838 | |||
| Maximum Drawdown | 55.18 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 9.1 | |||
| Downside Variance | 10.78 | |||
| Semi Variance | 5.94 | |||
| Expected Short fall | (4.45) | |||
| Skewness | 3.98 | |||
| Kurtosis | 22.95 |
Consider Rigel Pharmaceuticals' intraday indicators
Rigel Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rigel Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Rigel Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 19th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Rigel Stock media impact
Far too much social signal, news, headlines, and media speculation about Rigel Pharmaceuticals that are available to investors today. That information is available publicly through Rigel media outlets and privately through word of mouth or via Rigel internal channels. However, regardless of the origin, that massive amount of Rigel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Rigel Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Rigel Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Rigel Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Rigel Pharmaceuticals alpha.
Rigel Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Rigel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rigel Pharmaceuticals Corporate Management
| Raymond JD | General VP | Profile | |
| Tarek Sallam | Vice Marketing | Profile | |
| David Santos | Executive Officer | Profile | |
| Julie Patel | Senior Resources | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Rigel Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.